Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4652W HIGH $7.20
Volume
82.15 K
Value Traded
128.17 K
Short % Float
2.68%
-17.53%Week
-40.09%1 Month
+55.29%3 Month
+102.91%6 Month
-88.07%5 Year
-88.07%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.67 M
EPS (TTM)
-3.11
P/E Ratio
-
Ent. Value
-9.95 M
Total Shares
6.83 M
Float Shares
4.17 M
Insiders
38.98%
Institutions
34.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CALC Catalyst Timeline
Dated clinical, regulatory and corporate events for CalciMedica, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CalciMedica, Inc.
252Total events
14Upcoming
41Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Reverse Stock SplitCorporate
Common stock begins trading on split-adjusted basis on August 31, 2026
●Reverse Stock SplitCorporate
Reverse stock split effective at 5:00 p.m. ET on August 28, 2026
▼Equity OfferingCorporate
Completed private placement financing of up to approximately $49 million
▲Type C MeetingAuxoraFDA Meeting
FDA Type C Focused Meeting alignment on Phase 2b endpoints and enrichment strategy
acute pancreatitissource ↗
◆Timing GuidanceAuxoraPresentation
Expected FDA feedback on pivotal program design for Auxora in acute pancreatitis
acute pancreatitissource ↗
▲FDA Feedback ReceivedAuxoraFDA Meeting
FDA reviewed protocol amendment and interim safety data for KOURAGE trial; no comments received
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
◆FDA Feedback ReceivedAuxoraFDA Meeting
FDA feedback regarding potential future development of Auxora in AKI expected in 2Q 2026
acute kidney injury with acute hypoxemic respiratory failuresource ↗
▲Preclinical PoCAuxoraPreclinical
Preclinical data published in Human Immunology in April 2026
inflammatory and immune-mediated diseasessource ↗
▲Safety Data UpdateAuxoraClinical Data
Internal and external safety review of KOURAGE data found no drug-related toxicity
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
▲FDA Feedback ReceivedAuxoraFDA Meeting
Constructive FDA engagement for pivotal program in AP
acute pancreatitis (AP)source ↗
▲PublicationCM5480Presentation
JCI Insight publication of preclinical data for CM5480 in PAH
pulmonary arterial hypertension (PAH)source ↗
●Protocol AmendmentAuxoraTrial
Protocol amendment submitted to KOURAGE trial addressing design issues
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
▲Full ResultsAuxoraClinical Data
Phase 2b CARPO trial results published in eClinicalMedicine in February 2026
acute pancreatitis with systemic inflammatory response syndromesource ↗
▼Trial DiscontinuedAuxoraTrial
Phase 2 KOURAGE trial in AKI discontinued following IDMC recommendation
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
◆Topline ReadoutAuxoraClinical Data
Topline data expected from Phase 2 KOURAGE trial of Auxora in AKI
acute kidney injury with respiratory failuresource ↗
◆FDA Feedback ReceivedAuxoraFDA Meeting
FDA feedback expected to finalize pivotal trial design in AP in first half of 2026
acute pancreatitis (AP)source ↗
◆Trial InitiationAuxoraTrial
Final pivotal trial design expected in acute pancreatitis
acute pancreatitis (AP)source ↗
▼Trial DiscontinuedAuxoraTrial
KOURAGE trial discontinued following IDMC recommendation
acute kidney injury (AKI) with acute hypoxemic respiratory failure (AHRF)source ↗
◆Timing GuidanceAuxoraPresentation
Design of pivotal program in AP expected in 1H 2026
acute pancreatitis (AP)source ↗
◆Timing GuidanceAuxoraPresentation
Alignment on pivotal trial design anticipated around end of 2025
acute pancreatitis (AP)source ↗
◆Topline ReadoutAuxoraClinical Data
Topline data expected around end of 2025
acute kidney injury with acute hypoxemic respiratory failuresource ↗
◆Trial InitiationAuxoraTrial
Initiation of Phase 3 program expected around end of 2025 pending funding
acute pancreatitis with systemic inflammatory response syndromesource ↗
▲Preclinical PoCCM5480Preclinical
Publication in JCI Insight of preclinical data for CM5480 in PAH
pulmonary arterial hypertensionsource ↗
◆Enrollment UpdateAuxoraTrial
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in AKI with respiratory failure
acute kidney injury (AKI) with respiratory failuresource ↗
▲FDA Feedback ReceivedAuxoraFDA Meeting
Positive discussions with FDA on pivotal trial in acute pancreatitis
acute pancreatitis (AP)source ↗
◆Poster PresentationAuxoraPresentation
Poster presentation at ASN Kidney Week 2025 on Auxora in rat model of AKI
acute kidney injurysource ↗
▲Partnership / LicenseAuxoraCorporate
Collaboration with Telperian to integrate AI engine into analysis of Auxora clinical trials
◆Topline ReadoutAuxoraClinical Data
Topline data expected around end of 2025
acute kidney injury with acute hypoxemic respiratory failuresource ↗
◆Trial InitiationAuxoraTrial
Phase 3 program initiation expected around end of 2025 pending additional funding
acute pancreatitis with systemic inflammatory response syndromesource ↗
◆Oral PresentationPresentation
Presentation at H.C. Wainwright 27th Annual Global Investment Conference
◆Enrollment UpdateAuxoraTrial
Enrollment ongoing in Phase 2 KOURAGE trial
acute kidney injury (AKI) with respiratory failuresource ↗
◆FDA Feedback ReceivedAuxoraFDA Meeting
Productive initial meeting with FDA on AP program
acute pancreatitis (AP)source ↗
◆Oral PresentationPresentation
CalciMedica CEO to participate in fireside chat at H.C. Wainwright 4th Annual Kidney Virtual Conference
▲PublicationAuxoraPresentation
Publication in Thrombosis Update on D-dimer reduction from CARDEA trial
severe COVID-19 pneumoniasource ↗
●PublicationAuxoraPresentation
Publication in American Journal of Nephrology discussing design and rationale of Phase 2 KOURAGE trial
acute kidney injury with respiratory failuresource ↗
◆Oral PresentationAuxoraPresentation
Symposium 'Auxora for the Treatment of AKI' at 43rd Vicenza Course AKI-CRRT-EBPT
acute kidney injury (AKI)source ↗
●PublicationAuxoraPresentation
Publication in American Journal of Nephrology on KOURAGE study design
acute kidney injury (AKI) with respiratory failuresource ↗
●Oral PresentationAuxoraPresentation
Symposium at 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting
acute kidney injury (AKI)source ↗
◆End Of Phase 2 MeetingAuxoraFDA Meeting
End-of-Phase 2 meeting with FDA planned around middle of 2025
acute pancreatitis with systemic inflammatory response syndromesource ↗
Past FDA Catalysts and PDUFA Decisions
How CALC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | CRSPA | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 81%
Micro Cap(rank 535 of 660)
Percentile Rank
CalciMedica, Inc. faces pipeline headwinds (25/100), with $400M risk-adjusted pipeline value, led by CM-4620 Injectable Emulsion or CM-4620-IE in Acute Pancreatitis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CM-4620 Injectable Emulsion or CM-4620-IE Small moleculeCompletedNCT04681066 | Acute Pancreatitis | Phase 2 | COMPLETED | 216 | May 15, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CALC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Auxora | acute pancreatitis | Phase 2b | 2026-07-29 | 100% reduction in new-onset severe respiratory failureRead More | CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zaytsev EvgenyDirector | Grant/Award | 20,000 20,000 held | $0.00 | 07/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CALC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.2 % (100 %) | 4.51 M | 683.90 K |
CALC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CALC ranks across every disease it competes in
Competitive Position is a premium feature
See how CALC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCALC News
CALC▼ -6.9%on this news
CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CalciMedica, a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company focuses on developing CRAC channel inhibition therapies for serious diseases. Its pipeline includes Auxora, which has undergone extensive patient evaluation, and CM5480, with an IND submission expected in mid-2027.
Read more →CALC▼ -20%on this news· ran to -32% by day 3
CalciMedica Announces One-for-Five Reverse Stock Split
CalciMedica Inc. announced a 1-for-5 reverse stock split effective August 28, 2026, to comply with Nasdaq listing requirements. This action reduces the number of outstanding shares from approximately 34.5 million to about 6.9 million. The split-adjusted trading will commence on August 31, 2026. The company aims to enhance its market position and maintain compliance with Nasdaq standards.
Read more →CALCCalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica has reported its financial results for the second quarter of 2026, highlighting a successful private placement financing of approximately $49 million. This funding aims to support the advancement of their pulmonary hypertension program, with proof-of-concept data for Auxora in pulmonary arterial hypertension expected by mid-2027. Additionally, the company anticipates submitting an IND for CM5480 in the same timeframe.
Read more →CALCCalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
CalciMedica has announced FDA alignment on the Phase 2b trial design for Auxora in treating acute pancreatitis. The primary endpoint will focus on new-onset severe respiratory failure, with secondary endpoints including multi-organ failure. This alignment is seen as a crucial step towards establishing the first U.S. pivotal program for a therapeutic candidate in this area.
Read more →CALC▼ -25.6%on this news
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica has announced a private placement financing of up to $49 million to support its pulmonary hypertension program. The funds will be used for a Phase 1b proof-of-concept study of Auxora in patients with pulmonary arterial hypertension, with data expected by mid-2027. Additionally, the financing will aid in advancing CM5480 towards IND clearance, also anticipated by mid-2027.
Read more →CALC▼ -25.6%on this newsshared move
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica has received FDA confirmation to proceed with the clinical development of Auxora in the Phase 2 KOURAGE trial for acute kidney injury. The FDA reviewed a protocol amendment and interim safety data, resulting in no comments or questions, allowing patient dosing to continue. The company had previously paused enrollment due to safety concerns but found no drug-related toxicity.
Read more →CALC▲ +6.6%on this news· ran to +17% by day 1
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica reported its first-quarter financial results for 2026, highlighting key updates on its clinical programs. The company is in active discussions with the FDA regarding its Auxora program for acute pancreatitis and expects feedback in the second quarter of 2026. Positive Phase 2b trial results were published, indicating Auxora's efficacy in treating patients with acute pancreatitis. Additionally, preclinical studies for CalciMedica's CM5480 candidate in pulmonary hypertension are underway, with an IND submission anticipated in 2027.
Read more →CALC▲ +14.4%on this news· ran to +43% by day 3
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica reported its 2025 financial results, highlighting no drug-related toxicity in the Phase 2 KOURAGE trial for acute kidney injury. The company anticipates finalizing the pivotal program design for acute pancreatitis in the first half of 2026 and advancing its second CRAC channel inhibitor, CM5480, for pulmonary arterial hypertension. Despite a net loss of $29.6 million, CalciMedica's cash position is expected to sustain operations into late 2026.
Read more →CALC▼ -75.6%on this news· ran to -87% by day 3
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
CalciMedica has announced the discontinuation of its Phase 2 KOURAGE trial for Auxora in patients with acute kidney injury, following a recommendation from the Independent Data Monitoring Committee due to safety concerns. The company plans to reevaluate the trial design and patient enrollment criteria based on a comprehensive review of the unblinded clinical data. Despite this setback, CalciMedica remains optimistic about Auxora's potential in treating acute inflammatory conditions.
Read more →CALCCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica has reported its financial results for Q3 2025, highlighting ongoing enrollment in the Phase 2 KOURAGE trial for Auxora in acute kidney injury. The company is optimistic following positive discussions with the FDA regarding a pivotal trial in acute pancreatitis. Their cash position is projected to support operations into the second half of 2026, despite an increase in net loss compared to the previous year.
Read more →CALCCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
CalciMedica announced promising preclinical data for CM5480, a CRAC channel inhibitor, as a potential therapy for pulmonary arterial hypertension (PAH). The study demonstrated that CM5480, both as a monotherapy and in combination with existing treatments, significantly improved cardiac function and reduced pulmonary hypertension in animal models. These findings support further exploration of CM5480 in clinical settings.
Read more →CALCCalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
CalciMedica presented promising preclinical data on Auxora at ASN Kidney Week 2025, showing its effectiveness in reducing IL-17-related inflammation and improving kidney function in a rat model of acute kidney injury (AKI). The findings support the ongoing Phase 2 KOURAGE trial evaluating Auxora for severe AKI with respiratory failure. The study highlights Auxora's potential as a transformative therapy for critically ill patients.
Read more →CALCCalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
CalciMedica has partnered with Telperian to integrate AI tools for analyzing clinical trial data of Auxora, its lead compound. This collaboration aims to enhance the understanding of treatment effects across patient subgroups and refine pivotal trial designs. The partnership is expected to expedite insights into the drug's efficacy for acute inflammatory and immunologic conditions.
Read more →CALC▲ +14.8%on this news
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Rachel Leheny will discuss the company's innovative therapies targeting CRAC channels for inflammatory and immunologic diseases. CalciMedica's lead product, Auxora, has shown positive results in clinical trials and is being evaluated in multiple ongoing studies.
Read more →CALC▼ -10.1%on this news
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica announced its financial results for the second quarter of 2025, highlighting ongoing enrollment in the Phase 2 KOURAGE trial for Auxora targeting acute kidney injury (AKI) with respiratory failure, with data expected in early 2026. The company reported productive discussions with the FDA regarding a pivotal trial for Auxora in acute pancreatitis, anticipated by the end of 2025. Despite these developments, CalciMedica reported an increased net loss and a decline in other income, although its cash position remains strong to support operations into mid-2026.
Read more →CALCCalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
CalciMedica Inc. will participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025. CEO Rachel Leheny will engage in a fireside chat, which will be accessible via a live webcast. The company focuses on CRAC channel inhibition therapies for inflammatory and immunologic diseases, with promising clinical results from its lead product candidate, Auxora.
Read more →CALCCalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
CalciMedica has published a manuscript in the American Journal of Nephrology detailing the design and rationale of its Phase 2 KOURAGE trial for Auxora in treating acute kidney injury (AKI) with respiratory failure. The study aims to enroll around 150 patients and assess the efficacy of Auxora, which has shown positive results in preclinical models and previous trials. The trial's primary endpoint focuses on days alive without the need for a ventilator or dialysis.
Read more →CALCCalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
CalciMedica Inc. announced its participation in the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting, where it will present a symposium on 'Auxora for the Treatment of AKI'. The event will feature several presentations by leading experts discussing CRAC channels and their role in AKI. Webcasts of the presentations will be available on CalciMedica's investor relations website.
Read more →CALCCalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica has reported its financial results for the first quarter of 2025, revealing a net loss of $5.9 million amidst ongoing clinical trials. Notably, the company is continuing enrollment in the Phase 2 KOURAGE trial for its lead product, Auxora, with data results anticipated by the end of 2025. A post-hoc analysis demonstrated a significant reduction in mortality among patients treated with Auxora for acute kidney injury. The company's cash position is projected to sufficiently support operations into mid-2026, despite the recent financial losses.
Read more →CALCCalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Inc. announced its upcoming presentations at two significant medical meetings: Digestive Disease Week 2025 and the American Society of Nephrology conference. The company's Chief Medical Officer, Sudarshan Hebbar, will participate in an oral presentation and a panel discussion, while a poster presentation will also feature important findings related to acute pancreatitis. CalciMedica's focus on CRAC channel inhibition aims to address significant health challenges in inflammatory and immunologic diseases. The involvement in these events signals the company's ongoing commitment to advancing its research and development efforts.
Read more →About CalciMedica, Inc.
Headquarters505 COAST BOULEVARD SOUTH, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next CALC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime